Key takeaways
- Capsaicin is the pungent compound in hot peppers. Sweet bell peppers, often called capsicum, are not an equivalent source (Pepper chemistry).
- The reviewed human evidence is insufficient to recommend oral capsaicin for routine treatment of IBS, reflux, ulcers or intestinal-barrier disease (Small sensory study; Acute reflux physiology; Healthy-volunteer challenge; Short microbiome pilot).
- Small experiments support changes in gut sensation. A reduction in burning does not establish disease healing (Sensory endpoint; Esophageal infusion).
- The Italian IBS trial has a pharmaceutical-company coauthor; the cayenne pilot reports spice-industry funding. These relationships qualify interpretation and do not make a result false by themselves (IBS affiliations; Pilot funding).
- Concentrated extracts and extreme-hot-food challenges carry risks. The study protocols reviewed here do not establish a personal gut-treatment regimen (Acute human risk assessment; Research protocol).
Direct answer: Capsaicin can alter digestive sensation, but the reviewed clinical evidence does not establish dependable treatment of IBS, reflux, ulcers or intestinal-barrier disease. Small studies tested specific chili preparations, routes and selected patients. Less burning does not demonstrate healing, and a larger IBS study found no significant pain or bloating advantage over placebo. Enjoying tolerated spicy food is a food choice; it is not a validated supplement regimen. Concentrated products can provoke symptoms (Small IBS-D sensory trial; IBS comparison; Acute stomach experiment; Injury surrogates; Microbiome pilot; NIDDK dietary guidance).
The treatment verdict is an editorial, claim-level judgment based on small selected samples, preparation-specific testing and limited clinical outcomes in the reviewed studies. It is not a calculated probability or proof that capsaicin can never help anyone. Financial relationships and missing disclosures are assessed separately.
Contents
- Evidence summary
- What capsaicin is
- Forms and grades
- How it works
- Hype versus evidence
- Benefits by claim
- What works and what does not
- Risks and side effects
- Interactions and evidence gaps
- Who should avoid it or seek advice
- Studied doses
- Animal and laboratory evidence excluded
- Funding, ownership and access limits
- Frequently asked questions
- Sources and funding notes
Evidence summary
Strength refers to the precise claim. Strong, Moderate, Weak and Insufficient describe evidential strength; funding tiers below are separate. No-conflict declarations and academic affiliations do not establish complete financial independence. Commercial and incompletely disclosed studies are assessed with their methods, reported relationships and remaining limits; they do not provide independently financed replication.
| Claim | Evidence | Source | Funding or conflict | Strength |
|---|---|---|---|---|
| Relieves functional dyspepsia | Small trial reports a symptom signal in its accessible abstract | Bortolotti 2002 | Complete original funding, conflicts and procurement inaccessible | Weak preliminary signal |
| Treats overall IBS symptoms | Burning/sensory changes without global symptom improvement | Aniwan 2014 | No financial support or conflicts declared; powder transaction terms unreported | Insufficient for routine treatment |
| Treats reflux | Acute physiology, not healing or chronic treatment | Patcharatrakul 2020 | University fund; no conflicts declared; material terms unreported | Insufficient |
| Prevents NSAID ulcers | Healthy-volunteer injury surrogates, not ulcer prevention | Mózsik 2005 | Sigma/Sanofi materials named; main cash funding/COI unreported | Insufficient |
| Eradicates H. pylori | Brief six-person jalapeño intervention found no suppression | Graham 1999 | Indexed NIH grants; complete original finances inaccessible | Insufficient |
| Improves microbiome or gut inflammation | Short pilot; no global diversity or measured inflammatory-marker improvement | Bu 2022 | AND Foundation/MSI and university support; direct spice-company link | Insufficient clinical evidence |
| Prevents digestive cancers | Spicy-food associations, not a capsaicin intervention | Chan 2021 | Public/charitable funds; no conflicts declared; donor chains not audited | Insufficient for causality |
What capsaicin is
Capsaicin is a member of the capsaicinoid family responsible for the heat of pungent Capsicum peppers. Capsicum names a plant genus; capsaicin names a molecule. Ordinary sweet bell peppers have essentially no capsaicin-associated heat. Eating a red bell pepper is therefore not equivalent to taking the red chili powders used in these experiments. Pepper color alone does not identify pungency. NIST’s explanation of pepper heat
Most human digestive experiments reviewed here tested chili powder or sauce. Results for those materials cannot automatically be attributed to one molecule or transferred to every extract. Composition, delivery site and prior tolerance matter (Powder protocol; Different powder preparation; Sauce infusion; Colon-release powder).
Forms and grades
| Form | What it means for interpreting evidence |
|---|---|
| Culinary hot chili or cayenne powder | A mixture; grams of powder do not specify milligrams of capsaicin (Composition and heat). |
| Standardized capsaicinoid extract | The percentage may refer to several capsaicinoids, not capsaicin alone; verify the actual amount and ingredients |
| Enteric-coated or delayed-release capsules | Change where exposure occurs; a different formulation cannot inherit another product’s results (Mixed release; Colon-release trial). |
| Non-pungent capsinoids, such as capsiate | Chemically related compounds, not interchangeable doses of capsaicin (Capsinoid chemistry). |
| Phenylcapsaicin | A synthetic analogue; evidence for it does not establish what ordinary chili or capsaicin does (Synthetic analogue). |
| Topical creams or patches | External-use medicines; never swallow them or repurpose them as gut treatments (Topical-system route). |
Capsiate is a related ester, not interchangeable capsaicin. The receptor paper reports Japanese public support and compounds provided by Ajinomoto; it does not specify free donation or payment terms. This nonclinical source is used for chemical identity. The phenylcapsaicin paper identifies a different synthetic analogue developed by aXichem. The topical-system label concerns external administration and neuropathic-pain indications (Chemistry and disclosures; Analogue identity; Product route).
“Food grade,” “natural,” and a high Scoville rating are not evidence of gastrointestinal efficacy. This review did not independently assay any retail product, verify its contamination testing, or establish equivalence to a trial material.
How it works
Capsaicin activates TRPV1, a sensory channel involved in responses to chemical irritation, heat, and acidity. That provides a plausible explanation for burning. Repeated exposure can sometimes reduce sensory responses, commonly described as desensitization. This is a proposed treatment mechanism, not a demonstrated repair mechanism (Sensory mechanism; Physiological adaptation).
In the Taiwan GERD experiment, ten of 17 enrolled adults completed intraesophageal chili-sauce infusions. Seven did not complete, mostly because they could not tolerate the procedure. Repeated exposure reduced perceived heartburn and a rapid-distension clearance reflex; it did not test swallowed capsules or demonstrate disease healing. McIlhenny Tabasco was named, but procurement and cash funding were not reported; the authors declared no conflicts (Complete Methods, Results and disclosures).
Three separate questions must be answered before recommending a treatment: Does the patient feel better? Is the underlying condition better controlled? Is the overall balance of benefit and harm favorable? A positive answer to the first cannot substitute for the other two.
Hype versus evidence
- “It burns, so it must be destroying the stomach.” Sensory burning does not, by itself, diagnose tissue injury. Severe or persistent symptoms still deserve attention
- “The burning eventually fades, so the gut has healed.” Adaptation is not evidence of ulcer healing, reduced reflux exposure, or restored intestinal permeability
- “It increases good bacteria.” A change in a bacterial genus is not automatically a measurable health benefit
- “It kills H. pylori in the laboratory.” Antimicrobial effects in a dish do not show eradication in a person
- “Spicy-food eaters have lower cancer risk.” Food-pattern associations cannot establish that a capsule prevents cancer
- “The authors declared no conflict, so the trial is independent.” Funding acknowledgments and employer affiliations must also be checked
These are methodological distinctions, not allegations that every positive finding is false. A useful test is to ask what was actually measured: a sensation score, a laboratory marker, an endoscopy finding, or a clinically important outcome.
Benefits by claim
Functional dyspepsia
Functional dyspepsia can include upper-abdominal discomfort, early fullness, or post-meal fullness; it is not the same diagnosis as an ulcer or reflux. NIDDK
The accessible primary abstract of the Italian dyspepsia trial reports 30 randomized participants, five weeks of 2.5 g/day red pepper powder and a symptom advantage over placebo from week three. GERD and IBS were excluded. Complete original methods, numerical tables, endpoint hierarchy, financing, conflicts and product procurement were not recovered. This remains a small preliminary symptom signal (Primary abstract).
The related 2002 NEJM correspondence describes the same group’s 30-patient work and is not independent replication. Its complete original table and financial disclosures were not recovered (Related primary record).
Grade: Weak preliminary symptom evidence. A small early trial with inaccessible complete methods does not define dependable treatment, the best preparation or long-term tolerability.
Irritable bowel syndrome
In the 16-person Thai IBS-D crossover study, six-week chili periods reduced test-meal burning and changed the first rectal sensory threshold. Pain and overall IBS symptoms did not significantly improve. Severe spicy-food reactions were excluded, early symptoms could worsen and incomplete blinding was acknowledged. The paper declares no financial support or conflicts; Nguan Soon powder is named, with purchase/donation terms unreported (Complete sensory trial and disclosures).
The complete 2011 Italian paper randomized 50 people: 23 to colon-release red pepper and 27 to placebo for six weeks. Six active participants stopped because of pain and eight reduced their dose. The detailed Results report no significant between-group pain or bloating difference. Late within-active changes and favorable final overall effectiveness ratings are separate findings. A SOFAR Medical Department coauthor and no-conflict declaration are reported, but cash funding and product purchase/donation terms are not. The positive abstract must be read alongside these main results (Publisher identity; Complete author-uploaded original).
Grade: Weak for sensory adaptation; Insufficient for routine IBS treatment. A changed test-meal sensation in selected IBS-D patients cannot establish benefit for every IBS subtype.
Reflux and heartburn
The 2020 university-funded crossover studied 15 adults with non-erosive GERD and 15 healthy volunteers after a single 2 g chili exposure. Abdominal burning and stomach accommodation increased in the GERD group; heartburn and acid regurgitation did not significantly differ. Supine SPECT testing and one-off exposure limit generalization. Powder from Artchit and commercial Ensure were named; transaction terms were unreported, and no conflicts were declared (Complete original study).
Grade: Insufficient as reflux treatment. NIDDK recommends discussing individual symptom-triggering foods and considering reduction or avoidance. This supports individualized tolerance, not a universal chili ban or a forced-tolerance regimen (GERD food guidance).
Ulcers, gastritis, and NSAID protection
The Hungarian report describes 84 healthy volunteers across several small experiments. Intragastric microgram doses affected acid output and ethanol/indomethacin injury surrogates; they did not establish diagnosed-ulcer healing, prevention of major bleeding or long-term NSAID protection. A chronic subgroup count differs between Methods and Results, and two-week pretreatment did not add protection. Sigma capsaicin and Sanofi-Synthelabo indomethacin were named; main cash-funding, conflict and procurement declarations were not reported (Original publication; Recovered complete original).
Grade: Insufficient for a clinical protection or healing claim. Do not use capsaicin to make an NSAID regimen “safe.” H. pylori and NSAIDs are leading ulcer causes; diagnosis and cause-specific treatment matter. NIDDK does not recommend a special diet as an ulcer treatment. Ulcer causes, ulcer diet guidance
H. pylori infection
The primary abstract reports 12 H. pylori-infected adults, six tested with jalapeño meals, and no suppression on brief urea-breath-test measurements. This was not a powered, long-course eradication trial. Primary grant metadata lists NIH/NCI CA67469 and NIH/NIDDK DK53659; the complete original methods, tables, financial disclosures and product transactions remain inaccessible (Primary abstract and grant record).
Grade: Insufficient for eradication. This small brief pilot does not justify substituting capsaicin for prescribed infection treatment; it also cannot disprove every possible preparation.
Microbiome, intestinal inflammation, and “leaky gut”
The cayenne crossover recruited 44 people and analyzed 29 paired datasets from five-day periods with a two-day washout. It found selected microbial signals without global diversity, stool-calprotectin or lipocalin improvement. Short exposure, missing data, washout and unassayed capsaicin content limit interpretation. Funding included AND Foundation/MSI A47020 and MSU resources; MSI acknowledges McCormick support. No conflicts were declared, but this is commercially linked evidence (Complete trial and funding; MSI corporate support).
The phenylcapsaicin report tests a different synthetic analogue during an eight-week calorie-restricted diet and walking program. Zonulin was a secondary surrogate, not a measured digestive-treatment outcome. The paper contains inconsistent enrollment/age reporting. It lists Lucas Altepost and Erik Lager; aXichem’s annual report documents their management and shareholding roles, and its 2025 release confirms Lager’s company role since 2019. The paper’s cash funding, material transactions and complete endpoint reporting remain unresolved. None establishes that capsaicin repairs a diagnosed intestinal-barrier disorder (Original analogue report; Author management and holdings; Lager role confirmation).
Grade: Insufficient for clinically meaningful barrier repair. The reviewed capsaicin pilot and separate analogue biomarker report do not establish that treatment claim.
Digestive cancer prevention
The China Kadoorie Biobank analysis included 510,101 adults and about ten years of follow-up. Self-reported spicy-food frequency was associated with some digestive-cancer outcomes; it was not a measured capsaicin dose or randomized intervention. Stomach and colorectal associations attenuated to null in sensitivity exclusions for prior disease/early follow-up, consistent with reverse-causation concerns. Residual confounding remains (Complete cohort Methods and Results).
Grade: Insufficient for causal cancer prevention. Food habits can change with early disease, and smoking, alcohol, diet and infection can confound associations. The cohort did not test capsaicin supplements or cancer treatment.
What works and what does not
| Claim | Verdict | Notes |
|---|---|---|
| Predictably improves gut health for most users | Not established | No defensible general recommendation follows from the reviewed studies (Selected sensory experiment; IBS comparisons). |
| Alters gastrointestinal sensation | Supported narrowly | A physiological effect is not the same as an effective treatment (Sensation; Clearance physiology). |
| Treats dyspepsia or IBS | Unconfirmed | Better independent, adequately powered clinical trials are needed (Dyspepsia abstract only; IBS complete original). |
| Heals reflux, ulcers, or the intestinal barrier | Not established | Sensory and surrogate outcomes cannot stand in for healing (Acute reflux experiment; Healthy injury surrogates; Different analogue). |
| Eradicates infection or treats cancer | Unsupported | Do not replace appropriate medical care (Brief infection pilot; Food cohort). |
| Whole-food use according to tolerance | A food choice | Enjoyment is separate from a therapeutic claim (Individual symptom triggers). |
Risks and side effects
| Aspect | Finding | Source |
|---|---|---|
| Digestive discomfort | Burning, nausea, vomiting, and abdominal pain can occur, especially with concentrated exposure | BfR human-risk assessment |
| Early adaptation period | Symptoms can initially worsen; this does not prove eventual benefit | Aniwan 2014 |
| Extreme-hot products | Rapid, high intake can provoke severe reactions; food matrix and individual tolerance affect risk | BfR |
| Skin and eye exposure | Capsaicin is an irritant; this chemistry source does not establish a specific handling or handwashing protocol | NIST |
| Long-term concentrated use | The small selected, brief experiments do not establish long-term safety, rare-event rates or safety in vulnerable groups | Six-week study; Single exposure; Acute risk scope |
Safety: Do not dismiss severe symptoms as “just the pepper.” Vomiting blood, black tarry stool, fainting, or persistent severe abdominal pain require urgent medical assessment. Trouble swallowing, unintended weight loss, or persistent indigestion also warrant evaluation. NIDDK ulcer warning signs, indigestion warning signs
BfR’s acute human-risk assessment could not derive a universal safe/unsafe threshold. Selected small-dose symptoms are not a universal danger cutoff, and a severe high-dose event is not a safe ceiling. Food matrix and tolerance matter. Chronic-risk assessment was outside this opinion; animal-toxicology findings are not used here to establish human treatment benefit (Human sections and assessment scope).
Interactions and evidence gaps
This is a bounded assessment, not an exhaustive interaction checker. Before concentrated supplement use, review the exact product and every medicine with a pharmacist or clinician (Supplement and medicine guidance).
| Substance or condition | Mechanism or concern | Severity or evidence status | Source |
|---|---|---|---|
| Aspirin | Accessible primary abstract: 15 healthy men, 400/800 micrograms capsaicin with aspirin; measured platelet response did not change | Does not establish bleeding safety, long-term safety or all antithrombotic combinations; complete methods/finances inaccessible | Sándor 2014 |
| Drugs metabolized by CYP enzymes | Primary abstract reports human liver-microsome and rat enzyme experiments | Nonclinical mechanisms do not establish patient interactions or permit dose calculations; complete original disclosures inaccessible | Zhang 2012 |
| Reflux or marked food-triggered symptoms | Additional irritation can complicate symptom control | Practical tolerability concern; avoid self-directed escalation | NIDDK |
| Multi-ingredient supplements | Other active ingredients may create separate risks | Assess the full label; “capsicum” alone does not characterize the product | FDA supplement guidance |
The cited aspirin experiment and CYP laboratory record do not establish compatibility with every medicine, dose, formulation or long-term combination. Do not stop or change a prescription medicine based on this article; seek professional advice about the actual product.
Who should avoid it or seek advice
- Anyone with a known allergy to the preparation should avoid it (Exact product and ingredient precautions).
- People with active, unexplained, or worsening gastrointestinal symptoms should obtain a diagnosis before experimenting with concentrated extracts (Symptoms warrant evaluation).
- People taking regular medicines, particularly where an interaction could have serious consequences, should seek pharmacist or clinician advice (Medication review).
- Children and pregnant or breastfeeding people should not infer therapeutic supplement safety from these small adult experiments; relevant evidence was not established by the sources reviewed here (Adult study exclusions; Supplement precautions).
- Anyone who repeatedly develops pain, burning, vomiting, or diarrhea after chili should not assume enduring those symptoms will produce a therapeutic adaptation (Early worsening; Pain withdrawals).
These precautions concern medicinal experimentation and concentrated products. They do not imply that everyone must remove ordinary, tolerated amounts of chili from food.
Dosage and how it was studied
These are research exposures, not dosing instructions. The protocols reviewed here do not establish a personal oral capsaicin regimen for gut or stomach disease (Sensory-study protocol; Acute protocol; Limited aspirin experiment).
| Use case | Studied exposure | Duration | Notes |
|---|---|---|---|
| Functional dyspepsia | 2.5 g/day red pepper powder | Five weeks | Reported in primary abstract, not 2.5 g capsaicin; full methods, finances and procurement inaccessible (record) |
| IBS-D sensory study | 2.1 g/day chili powder, mixed-release capsules | Six weeks per period | Calculated 2.52 mg/day from reported 1.2 mg/g. Nguan Soon powder; purchase/donation terms unreported; not a recommendation (complete original) |
| Acute stomach experiment | 2 g chili containing 1.46 mg capsaicin | Single exposure | Artchit powder and Ensure in a controlled provocation protocol; no therapeutic regimen (complete original) |
| Aspirin platelet experiment | 400 or 800 micrograms capsaicin | Acute sessions | Primary abstract only; narrow platelet endpoint, not ulcer prevention or universal medicine safety (record) |
Do not convert these figures into spoonfuls of an unassayed powder, substitute extracts milligram-for-milligram, or mistake micrograms for milligrams. The calculation above describes one study material and cannot be generalized to another chili variety (Composition-specific calculation; Different preparation).
Animal and in vitro evidence excluded from conclusions
Cell and animal experiments on H. pylori inhibition, inflammatory signaling, tumor cells, microbial composition, and barrier function were not used to establish human efficacy or safety. “Human cells” in a laboratory are not a human clinical trial.
Chemical-identity research is retained only to distinguish capsinoids from capsaicin. The CYP laboratory study is retained only to explain why a proposed interaction remains unconfirmed. No concentration from these experiments is converted into a human treatment dose. Commercial phenylcapsaicin evidence also cannot be substituted for evidence about capsaicin.
Funding, ownership and access limits
Research funding at a glance
19 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
Capsaicin-containing products can involve growers, food processors, ingredient suppliers, brands, retailers and proprietary-formulation makers. Raw-material origin, manufacturing country, seller headquarters and regulatory jurisdiction are separate facts. This review checks selected disclosed relationships; it does not identify every patent holder, product-rights owner or retail supply chain.
The IBS original lists a SOFAR Medical Department coauthor despite a no-conflict declaration; cash funding and material terms remain unreported. The cayenne paper lists AND Foundation/MSI A47020, and MSI acknowledges McCormick financial support. The phenylcapsaicin authors Altepost and Lager also have documented aXichem management/shareholding interests. These are specific disclosed relationships, not proof that a sponsor dictated every result (IBS original; Grant disclosure; MSI FAQ; Funding guidelines; Author corporate roles; Lager confirmation).
Funding does not prove falsehood. Methodological strength, source role and reported financial relationships are assessed separately. Commercial involvement or missing disclosures prevent a claim of fully verified financial independence.
Follow the money
- McCormick, USA → corporate financial support → McCormick Science Institute (Own FAQ; US headquarters).
- AND Foundation/MSI award A47020 → named grant → Bu 2022 pilot; MSU resources also acknowledged (Original funding statement).
- SOFAR Medical Department, Italy → author affiliation → 2011 IBS paper; trial payment and control not reported (Complete original affiliation).
- Chulalongkorn Ratchadapiseksompotch Fund, Thailand → declared support → 2020 acute experiment (Original funding).
- Aniwan 2014, Thailand → no financial support or conflicts declared; named powder procurement terms unreported (Original footnotes and Methods).
This linked relationships list records funding, affiliations and operation locations, not ownership of capsaicin or proof of result control. McCormick identifies its Hunt Valley, Maryland headquarters. Alfasigma’s 2022 notice identifies its acquisition of Italian SOFAR; Fine Foods completed a 100% Sofar acquisition from Alfasigma in June 2026, while Alfasigma retained products under a manufacturing arrangement. These later ownership events do not identify who paid for or controlled the 2011 trial (McCormick location; Historical SOFAR acquisition; 2026 completed transaction).
Source credibility scorecard
Financial tiers describe reported relationships: Tier 1 denotes disclosed public/academic support without an identified subject-industry funder at that level; Tier 2 indirect interests; Tier 3 commercial author/employer interests; Tier 4 maker, seller, sponsor or supplied-product involvement. Unclassified means the necessary finance is unresolved. A no-conflict statement alone does not clear procurement or every resource. Reliability grades A–D apply to the limited source role, not automatic clinical efficacy or a methodological quality score.
| Source | Money, employer, or backer; country | Tier and grade | Accuracy incentive and remaining limitation |
|---|---|---|---|
| Aniwan 2014 | Thai university authors; no financial support/conflicts declared; Nguan Soon powder | Unclassified complete finances; B for sensory methods | Very small selected sample and incomplete blinding; product purchase/donation terms unreported |
| Patcharatrakul 2020 | University fund, Thailand; no conflicts declared; Artchit powder and Ensure | 1 at declared cash-funder level; B for acute physiology | One-off supine testing; no clinical healing; commercial product transaction terms unreported |
| Bortolotti 2002 and related NEJM letter | Bologna, Italy; full financing/COI/procurement inaccessible | Unclassified; B provisional for accessible records | Dyspepsia abstract and indexed related-letter portions only; full numerical methods not checked; no double counting |
| Bortolotti and Porta 2011 | University and SOFAR Medical Department authors, Italy; no COI declared | 3; C for financially qualified evidence | Complete original: pain/bloating between-group null, final effectiveness rating favorable; substantial active pain attrition; cash and material terms unreported |
| Mózsik 2005 | Hungarian institutions; Sigma capsaicin/Sanofi-Synthelabo indomethacin | Unclassified cash/COI; B for challenge observations | Complete main article has no separate funding/COI line; transaction terms unreported; healthy surrogates and subgroup-count discrepancy |
| Graham 1999 | Baylor/VA, USA; indexed NIH/NCI CA67469 and NIDDK DK53659 | 1 at indexed grant level; B provisional | Primary abstract and grants only; six-person brief jalapeño exposure; complete original methods, finances/COI and material terms unavailable |
| Bu 2022 | MSU plus AND Foundation/MSI A47020, USA; MSI McCormick support | 4; C for commercial relationship; clinically preliminary | No COI declared; 29 paired analyses, brief exposure, no global-diversity/inflammatory-marker benefit; transaction and total-budget terms unreported |
| Chan 2021 | Chinese public programs; UK public/charity funds; Kadoorie Foundation Hong Kong | 1 at declared funder level; B for observational context | No COI declared; unmeasured capsaicin dose, confounding/reverse causation; ultimate donors and investments not comprehensively traced |
| Chen 2016 | Tzu Chi investigators, Taiwan; McIlhenny Tabasco named | Unclassified cash; B for experimental physiology | No COI declared; no separate main funding line; procurement/philanthropic chains unknown; ten selected completers, artificial route |
| Sándor 2014 | Pécs investigators, Hungary; full funding/COI unavailable | Unclassified; B provisional for primary abstract | 15 healthy men; acute platelet endpoint; full original restricted/inaccessible, no bleeding or all-drug assurance |
| Capsiate laboratory paper | Japanese MEXT partial grant support; Ajinomoto provided compounds | 4 for supplied product; C for chemistry-only role | No COI declared; nonclinical; purchase/donation/payment terms not stated; no human efficacy inference |
| CYP laboratory paper | Beijing academic authors, China; full original funding/COI inaccessible | Unclassified; B provisional for abstract mechanism | Human liver microsomes and rats, not patients; full methods/procurement unverified |
| Phenylcapsaicin report | aXichem analogue; Altepost/Lager management and shareholdings documented (annual report; Lager role) | 3; C for interested analogue context | Separate compound; enrollment/age inconsistencies and secondary zonulin surrogate; complete trial cash/procurement and endpoint tables unresolved |
| BfR risk assessment; policy; facts | German federal budget/public research; Berlin; states it rejects industry funding | 1 at institutional remit; A for risk framing | Relevant acute human-risk sections read; not every expert or underlying study finance, long-term safety or clinical efficacy verified |
| NIDDK clinical guidance and budget | US NIH statutory/public budget context | 1 institution level; A for its clinical guidance | Expert-reviewed general guidance; no capsaicin trial efficacy or full institutional/individual cash-chain clearance |
| NIST pepper explanation and budget | US Commerce agency; government budget oversight | 1 institution level; A for finite chemistry | Educational/measurement context only; no digestive-treatment result or specific handwashing protocol |
| FDA supplement guidance and budget | FY2025 agency: 51% public budget authority/49% user fees; food program 1.1% user fees | 2 institution level; A for own rules | Different program revenue shares matter; institutional user fees do not prove capsaicin trial influence or food-guidance sponsorship |
| DailyMed capsaicin label | Averitas Pharma, United States; label identifies Grünenthal affiliation and LTS manufacture in Germany; hosted by NLM | 4; C for route/label facts | Legally regulated labeling; product-specific and commercially originated; no oral-gut benefit inference |
| MSI, McCormick, Alfasigma/Fine Foods and aXichem primary disclosures | Corporate/corporate-funded sources; USA, Italy, Sweden | 4; C for interested self-disclosure | Own support, locations and dated ownership/management statements only; not independent clinical efficacy (MSI; HQ; 2022; 2026; aXichem HQ) |
The small Thai sensory and acute-stomach experiments partly share investigators; they do not provide broad independent multicountry replication. Other reviewed human settings include Italy, Hungary, Taiwan, China and the USA. Country describes setting and generalizability, not citizenship, financial independence or clinical reliability.
aXichem identifies a Malmö headquarters and phenylcapsaicin patent portfolio. Its dated annual report and 2025 release document commercial roles/holdings for named analogue-paper authors. These sources establish interests in the analogue, not ownership of ordinary capsaicin. Every ultimate beneficial owner, investor and trial transaction was not comprehensively audited (Corporate contact; Research and patents; Management/holdings; Lager role).
The cohort names Kadoorie Charitable Foundation, Wellcome, Chinese public programs and Oxford core support from BHF, MRC and Cancer Research UK; it declares no conflicts. Those original disclosures were read. Complete charity donor/investment chains and all institutional resources were not audited, so this is not a claim of exhaustive financial independence (Original funders and COI).
Regulatory status
In the United States, dietary supplements are regulated, but FDA does not generally approve them for safety or effectiveness before marketing. A supplement label is therefore not proof of a gut-treatment indication. FDA
Capsaicin’s use in an approved topical pain product does not establish approval, efficacy, or dosing for oral gastrointestinal treatment. Product label
No worldwide authorization claim is made: rules differ by product and jurisdiction, and the legal status of a particular extract must be checked separately.
Frequently asked questions
Does the capsicum in a salad contain the capsaicin used in gut trials?
If “capsicum” means ordinary sweet bell pepper, it is not equivalent to pungent chili. The plant name alone is insufficient to identify capsaicin exposure. NIST
Should I build up chili tolerance to treat IBS?
The evidence does not justify that recommendation. Being able to tolerate a spicy test meal is different from obtaining reliable control of a chronic disorder (Sensory versus global symptoms; Pain and bloating comparison).
Does chili cause all stomach ulcers?
No. H. pylori and NSAID use are the common causes. But that does not make high-dose extracts a treatment or make persistent pain safe to ignore. NIDDK
Is a non-burning capsule safer or more effective?
Not necessarily. A non-burning product may be a different compound, or release farther down the gut. The colon-release IBS trial still had pain withdrawals. Reduced mouth burn does not establish favorable clinical benefit–risk (Capsinoid identity; Colon-release trial).
Can capsaicin cure H. pylori or repair “leaky gut”?
The brief jalapeño pilot did not suppress H. pylori, and the separate phenylcapsaicin biomarker study does not establish ordinary capsaicin treatment of intestinal-barrier disease. Appropriate care depends on the actual diagnosis (Primary pilot abstract; Different analogue and endpoint).
Is it safe with every medicine?
That has not been established. A narrow negative interaction experiment cannot clear all drugs, doses, formulations, or long-term combinations (Limited platelet experiment; Nonclinical CYP record).
Sources and funding notes
Primary clinical methods/results and front/back financial statements were checked where accessible. Full-original, primary-abstract and partial-record access are distinguished below. Corporate sources document their own relationships only. This is a targeted review, not a preregistered systematic review or a complete investigation of every author’s finances.
- Aniwan S, Gonlachanvit S. J Neurogastroenterol Motil. 2014;20:400–406. DOI 10.5056/jnm14022. Complete main Methods/results/footnotes read; no financial support or conflicts declared. Nguan Soon powder transaction terms unreported (Full original).
- Patcharatrakul T et al. Nutrients. 2020;12:3740. DOI 10.3390/nu12123740. Complete main original read; university fund and no COI declared. Artchit powder/Ensure transactions unreported; acute physiology only (Full original).
- Bortolotti M et al. Aliment Pharmacol Ther. 2002;16:1075–1082. Primary abstract only; complete original methods, tables, finance/COI and procurement inaccessible. Related NEJM letter partially indexed, not an independent replication (Publisher identity; Primary abstract; Related correspondence).
- Bortolotti M, Porta S. Dig Dis Sci. 2011;56:3288–3295. Complete author-uploaded published original read: between-group pain/bloating null, final effectiveness rating favorable. SOFAR coauthor; no COI declared; main cash/procurement terms unreported (Publisher identity; Actual full original).
- Mózsik G et al. World J Gastroenterol. 2005;11:5180–5184. Complete healthy-challenge original read. Sigma/Sanofi-Synthelabo materials named; separate main cash funding/COI and supply terms not reported; chronic subgroup count inconsistent (Publication; Full original).
- Graham DY et al. Am J Gastroenterol. 1999;94:1200–1202. Primary abstract and NIH/NCI CA67469/NIDDK DK53659 grant metadata read. Complete final methods/tables/financial and material declarations inaccessible (Primary record).
- Bu S et al. Life. 2022;12:1849. Complete main original read; 29 paired analyses, no global-diversity/stool-inflammatory-marker advantage. AND Foundation/MSI A47020 and university support; no COI declared. Procurement and all budget terms unreported (Publisher identity; Full original).
- Chan WC et al. Int J Epidemiol. 2021;50:199–211. Complete relevant main Methods/results/Funding/COI read. Observational food associations, not measured capsaicin treatment; public/charitable funders and no conflicts declared, donor chains not fully audited (Full original).
- Chen and colleagues. Influence of capsaicin infusion on secondary peristalsis in GERD. 2016. Complete main original read; ten of 17 completed. No COI declared; separate cash funding absent, Tabasco purchase/donation terms unreported. Artificial-route physiology only (Full original).
- Sándor B et al. Acta Physiol Hung. 2014;101:429–437. Primary abstract only; full original methods/tables/finance/COI remain inaccessible. Acute healthy-male platelet experiment, not bleeding or broad medicine safety (Primary record).
- Zhang and colleagues. Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities. DOI 10.1080/10286020.2012.656605. Primary abstract only; complete original methods/disclosures unavailable. Nonclinical interaction mechanism, not a patient result (Primary record).
- Shintaku K et al. Br J Pharmacol. 2012;165:1476–1486. Complete relevant chemistry/receptor main original and disclosures read. MEXT partial support; Ajinomoto provided compounds; no COI declared. Transaction terms unspecified; nonclinical identity role only (Full original).
- Framroze, Altepost and Lager. 2022 phenylcapsaicin/zonulin report. Main original HTML read; separate analogue and secondary surrogate, with enrollment/age reporting inconsistencies. Author commercial management/holdings corroborated; complete cash, procurement and numerical reporting unresolved (Original report; Dated annual report; Corporate role).
- BfR Opinion 027/2024: relevant original human acute-risk and uncertainty sections read; chronic assessment excluded. Institutional policy/facts read, not every expert or underlying-study financial relationship (Human risk opinion; Independence policy; Institutional facts).
- NIDDK: GERD diet, ulcer diet, ulcer causes and warnings, indigestion, budget. Clinical context rather than capsaicin efficacy.
- NIST: pepper-heat explainer, budget division. Ingredient distinction only.
- FDA funding facts; FDA supplement questions and answers; DailyMed topical-system label. Regulatory and route facts only.
- Interested corporate sources document their own financial support, locations and dated ownership/management statements: MSI FAQ/guidelines, current McCormick headquarters page, historical Alfasigma SOFAR acquisition, Fine Foods completed 2026 transaction, and aXichem contact/patents/author roles. They are not independent clinical outcome evidence (MSI FAQ; Grant guidelines; McCormick location; SOFAR 2022; SOFAR 2026; aXichem location; Patent portfolio; Dated management/holdings; Lager role).
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
